HAVCR1 and neoplasm: Recently, Lloyd Bod et al. published a study in Nature that identified the B-cell immune checkpoint T cell immunoglobulin and mucin domain 1 (TIM-1) and mechanistically elucidated that targeting TIM-1 enhances the responses to type I interferon (IFN-I), promotes B cells antigen presentation and activation, subsequently enhances anti-tumour responses of CD4+ and CD8+ T cells and inhibits tumour growth.